New generation antidepressants in painful diabetic neuropathy

Angela M. Gutierrez-Alvarez; Carlos B. Moreno

New generation antidepressants in painful diabetic neuropathy

Título traducido de la contribución: Antidepresivos de nueva generación en neuropatía diabética dolorosa

Angela M. Gutierrez-Alvarez
, Carlos B. Moreno

Producción científica: Contribución a revista › Artículo de Investigación › revisión exhaustiva

Resumen

La incidencia de neuropatía diabética aumenta con la duración de la diabetes y el grado de hiper-glicemia. El dolor es uno de los síntomas más comunes e incapacitantes de la neuropatía diabética y su control farmacológico es complejo. La efectividad de los antidepresivos ha sido descrita en diferentes tipos de dolor neuropático, pero su verdadera efectividad, al ser usados como analgésicos en el dolor en la neuropatía diabética, aún es controvertida. Objetivo: Realizar una revisión siste-mática y meta-análisis para determinar el nivel de evidencia en relación con la potencia analgésica de estos nuevos antidepresivos para el manejo del dolor en el paciente con neuropatía diabética dolorosa. Métodos: La búsqueda cubrió las bases de datos Cochrane, MEDLINE, EMBASE y LI-LACS entre enero de 2000 y agosto de 2007. De cada artículo se obtuvo la siguiente información: criterios para diagnóstico de neuropatía diabética, edad promedio de los pacientes, antidepresivo recibido y dosis, tamaño de la muestra, duración de la enfermedad, seguimiento del tratamiento, medidas de desenlace, evaluación del dolor y medicación de rescate. Resultados: Se obtuvo un RR combinado de 1,67 (IC 95% 1,38 – 2,02). El NNT correspondiente para la Duloxetina fue de 6 (95% CI 5- 8), para obtener una analgesia superior a 50% en pacientes con dolor por neuropatía diabética. Discusión: Se ha demostrado que los antidepresivos son empleados con frecuencia y efectivos como analgésicos para el dolor por neuropatía diabética.

Título traducido de la contribución	Antidepresivos de nueva generación en neuropatía diabética dolorosa
Idioma original	Inglés estadounidense
Páginas (desde-hasta)	33-42
Número de páginas	10
Publicación	Revista Ciencias de la Salud
Estado	Publicada - ene. 1 2011

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Áreas temáticas de ASJC Scopus

Neurología

Acceder al documento

https://revistas.urosario.edu.co/index.php/revsalud/article/view/1547

Citar esto

@article{132ccfe11886493a830861c38265ed6e,

title = "New generation antidepressants in painful diabetic neuropathy",

abstract = "The incidence of diabetic neuropathy increases with the duration of diabetes and the degree of hyperglycaemia. Pain is one of the most common and incapacitating symptoms of diabetic neuropathy and its pharmacological control is complex. The effectiveness of antidepressive agents has been described in different types of neuropathic pain, but their effectiveness, when used as analgesics in painful diabetic neuropathy, still remains controversial. Objective: To review the possible role of new-generation antidepressive agents in the treatment of pain in diabetic peripheral neuropathy. This work has thus consisted of a meta-analysis for determining which antidepressive agent had the best analgesic potential in managing pain in patients suffering from painful diabetic neuropathy. Methods: This search covered the Cochrane, MEDLINE, EMBASE and LILACS databases, between January 2000 and August 2007. The following information was obtained from each article: criteria for diagnosing diabetic neuropathy, patients' age average, antidepressant drug received and dose, sample size, duration of the disease and treatment follow-up, outcome measurement, evaluation of pain and rescue medication. Results: A combined RR: 1.67 (95\% CI 1.38 - 2.02) was obtained; this result indicated that the antidepressive agent duloxetine, was effective for controlling pain in diabetic neuropathy. The corresponding NNT for Duloxetine was established, according to our interests; NNT = 6 (95\% CI 5- 8) for achieving greater than 50\% analgesia in patients suffering from painful diabetic neuropathy. Discussion: Antidepressive agents are frequently employed in the specific case of diabetic neuropathy; their analgesic benefit has been demonstrated.",

author = "Gutierrez-Alvarez, \{Angela M.\} and Moreno, \{Carlos B.\}",

year = "2011",

month = jan,

day = "1",

language = "English (US)",

pages = "33--42",

journal = "Revista Ciencias de la Salud",

issn = "1692-7273",

publisher = "Universidad del Rosario",

}

TY - JOUR

T1 - New generation antidepressants in painful diabetic neuropathy

AU - Gutierrez-Alvarez, Angela M.

AU - Moreno, Carlos B.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The incidence of diabetic neuropathy increases with the duration of diabetes and the degree of hyperglycaemia. Pain is one of the most common and incapacitating symptoms of diabetic neuropathy and its pharmacological control is complex. The effectiveness of antidepressive agents has been described in different types of neuropathic pain, but their effectiveness, when used as analgesics in painful diabetic neuropathy, still remains controversial. Objective: To review the possible role of new-generation antidepressive agents in the treatment of pain in diabetic peripheral neuropathy. This work has thus consisted of a meta-analysis for determining which antidepressive agent had the best analgesic potential in managing pain in patients suffering from painful diabetic neuropathy. Methods: This search covered the Cochrane, MEDLINE, EMBASE and LILACS databases, between January 2000 and August 2007. The following information was obtained from each article: criteria for diagnosing diabetic neuropathy, patients' age average, antidepressant drug received and dose, sample size, duration of the disease and treatment follow-up, outcome measurement, evaluation of pain and rescue medication. Results: A combined RR: 1.67 (95% CI 1.38 - 2.02) was obtained; this result indicated that the antidepressive agent duloxetine, was effective for controlling pain in diabetic neuropathy. The corresponding NNT for Duloxetine was established, according to our interests; NNT = 6 (95% CI 5- 8) for achieving greater than 50% analgesia in patients suffering from painful diabetic neuropathy. Discussion: Antidepressive agents are frequently employed in the specific case of diabetic neuropathy; their analgesic benefit has been demonstrated.

AB - The incidence of diabetic neuropathy increases with the duration of diabetes and the degree of hyperglycaemia. Pain is one of the most common and incapacitating symptoms of diabetic neuropathy and its pharmacological control is complex. The effectiveness of antidepressive agents has been described in different types of neuropathic pain, but their effectiveness, when used as analgesics in painful diabetic neuropathy, still remains controversial. Objective: To review the possible role of new-generation antidepressive agents in the treatment of pain in diabetic peripheral neuropathy. This work has thus consisted of a meta-analysis for determining which antidepressive agent had the best analgesic potential in managing pain in patients suffering from painful diabetic neuropathy. Methods: This search covered the Cochrane, MEDLINE, EMBASE and LILACS databases, between January 2000 and August 2007. The following information was obtained from each article: criteria for diagnosing diabetic neuropathy, patients' age average, antidepressant drug received and dose, sample size, duration of the disease and treatment follow-up, outcome measurement, evaluation of pain and rescue medication. Results: A combined RR: 1.67 (95% CI 1.38 - 2.02) was obtained; this result indicated that the antidepressive agent duloxetine, was effective for controlling pain in diabetic neuropathy. The corresponding NNT for Duloxetine was established, according to our interests; NNT = 6 (95% CI 5- 8) for achieving greater than 50% analgesia in patients suffering from painful diabetic neuropathy. Discussion: Antidepressive agents are frequently employed in the specific case of diabetic neuropathy; their analgesic benefit has been demonstrated.

M3 - Research Article

SN - 1692-7273

SP - 33

EP - 42

JO - Revista Ciencias de la Salud

JF - Revista Ciencias de la Salud

ER -

New generation antidepressants in painful diabetic neuropathy

Resumen

ODS de las Naciones Unidas

Áreas temáticas de ASJC Scopus

Acceder al documento

Huella

Citar esto